S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
Log in
NASDAQ:LOGC

LogicBio Therapeutics Competitors

$7.84
-0.53 (-6.33 %)
(As of 03/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$7.62
Now: $7.84
$8.67
50-Day Range
$7.76
MA: $8.51
$9.16
52-Week Range
$3.05
Now: $7.84
$10.00
Volume179,096 shs
Average Volume128,840 shs
Market Capitalization$249.20 million
P/E RatioN/A
Dividend YieldN/A
Beta1.34

Competitors

LogicBio Therapeutics (NASDAQ:LOGC) Vs. AERI, PASG, TSHA, BDTX, RUBY, and ALGS

Should you be buying LOGC stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to LogicBio Therapeutics, including Aerie Pharmaceuticals (AERI), Passage Bio (PASG), Taysha Gene Therapies (TSHA), Black Diamond Therapeutics (BDTX), Rubius Therapeutics (RUBY), and Aligos Therapeutics (ALGS).

Aerie Pharmaceuticals (NASDAQ:AERI) and LogicBio Therapeutics (NASDAQ:LOGC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, profitability and valuation.

Profitability

This table compares Aerie Pharmaceuticals and LogicBio Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aerie Pharmaceuticals-231.05%-135.57%-37.23%
LogicBio TherapeuticsN/A-117.64%-76.85%

Analyst Ratings

This is a breakdown of current ratings and price targets for Aerie Pharmaceuticals and LogicBio Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aerie Pharmaceuticals11902.73
LogicBio Therapeutics00303.00

Aerie Pharmaceuticals presently has a consensus target price of $25.50, suggesting a potential upside of 32.47%. LogicBio Therapeutics has a consensus target price of $18.50, suggesting a potential upside of 135.97%. Given LogicBio Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe LogicBio Therapeutics is more favorable than Aerie Pharmaceuticals.

Earnings and Valuation

This table compares Aerie Pharmaceuticals and LogicBio Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aerie Pharmaceuticals$69.89 million12.92$-199,580,000.00($3.40)-5.66
LogicBio TherapeuticsN/AN/A$-40,130,000.00($1.78)-4.40

LogicBio Therapeutics has lower revenue, but higher earnings than Aerie Pharmaceuticals. Aerie Pharmaceuticals is trading at a lower price-to-earnings ratio than LogicBio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

99.9% of Aerie Pharmaceuticals shares are held by institutional investors. Comparatively, 33.8% of LogicBio Therapeutics shares are held by institutional investors. 9.7% of Aerie Pharmaceuticals shares are held by insiders. Comparatively, 23.4% of LogicBio Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility and Risk

Aerie Pharmaceuticals has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, LogicBio Therapeutics has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500.

Summary

LogicBio Therapeutics beats Aerie Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Passage Bio (NASDAQ:PASG) and LogicBio Therapeutics (NASDAQ:LOGC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

Profitability

This table compares Passage Bio and LogicBio Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Passage BioN/AN/AN/A
LogicBio TherapeuticsN/A-117.64%-76.85%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Passage Bio and LogicBio Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Passage Bio02602.75
LogicBio Therapeutics00303.00

Passage Bio presently has a consensus target price of $25.5297, indicating a potential upside of 31.39%. LogicBio Therapeutics has a consensus target price of $18.50, indicating a potential upside of 135.97%. Given LogicBio Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe LogicBio Therapeutics is more favorable than Passage Bio.

Institutional & Insider Ownership

67.6% of Passage Bio shares are owned by institutional investors. Comparatively, 33.8% of LogicBio Therapeutics shares are owned by institutional investors. 23.4% of LogicBio Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Passage Bio and LogicBio Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Passage BioN/AN/AN/AN/AN/A
LogicBio TherapeuticsN/AN/A$-40,130,000.00($1.78)-4.40

Summary

Passage Bio beats LogicBio Therapeutics on 4 of the 7 factors compared between the two stocks.

Taysha Gene Therapies (NASDAQ:TSHA) and LogicBio Therapeutics (NASDAQ:LOGC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk and analyst recommendations.

Profitability

This table compares Taysha Gene Therapies and LogicBio Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Taysha Gene TherapiesN/AN/AN/A
LogicBio TherapeuticsN/A-117.64%-76.85%

Insider & Institutional Ownership

42.2% of Taysha Gene Therapies shares are owned by institutional investors. Comparatively, 33.8% of LogicBio Therapeutics shares are owned by institutional investors. 23.4% of LogicBio Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Taysha Gene Therapies and LogicBio Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Taysha Gene TherapiesN/AN/AN/AN/AN/A
LogicBio TherapeuticsN/AN/A$-40,130,000.00($1.78)-4.40

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Taysha Gene Therapies and LogicBio Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Taysha Gene Therapies00603.00
LogicBio Therapeutics00303.00

Taysha Gene Therapies currently has a consensus target price of $40.3333, indicating a potential upside of 72.36%. LogicBio Therapeutics has a consensus target price of $18.50, indicating a potential upside of 135.97%. Given LogicBio Therapeutics' higher probable upside, analysts plainly believe LogicBio Therapeutics is more favorable than Taysha Gene Therapies.

Summary

Taysha Gene Therapies beats LogicBio Therapeutics on 4 of the 6 factors compared between the two stocks.

LogicBio Therapeutics (NASDAQ:LOGC) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Valuation & Earnings

This table compares LogicBio Therapeutics and Black Diamond Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LogicBio TherapeuticsN/AN/A$-40,130,000.00($1.78)-4.40
Black Diamond TherapeuticsN/AN/A$-35,260,000.00($16.99)-1.40

LogicBio Therapeutics is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

33.8% of LogicBio Therapeutics shares are held by institutional investors. Comparatively, 65.8% of Black Diamond Therapeutics shares are held by institutional investors. 23.4% of LogicBio Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares LogicBio Therapeutics and Black Diamond Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
LogicBio TherapeuticsN/A-117.64%-76.85%
Black Diamond TherapeuticsN/A-22.28%-17.91%

Analyst Ratings

This is a breakdown of current ratings and target prices for LogicBio Therapeutics and Black Diamond Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
LogicBio Therapeutics00303.00
Black Diamond Therapeutics00403.00

LogicBio Therapeutics currently has a consensus price target of $18.50, suggesting a potential upside of 135.97%. Black Diamond Therapeutics has a consensus price target of $51.50, suggesting a potential upside of 117.02%. Given LogicBio Therapeutics' higher possible upside, equities research analysts clearly believe LogicBio Therapeutics is more favorable than Black Diamond Therapeutics.

Summary

Black Diamond Therapeutics beats LogicBio Therapeutics on 6 of the 9 factors compared between the two stocks.

LogicBio Therapeutics (NASDAQ:LOGC) and Rubius Therapeutics (NASDAQ:RUBY) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, valuation and earnings.

Profitability

This table compares LogicBio Therapeutics and Rubius Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
LogicBio TherapeuticsN/A-117.64%-76.85%
Rubius TherapeuticsN/A-77.33%-49.05%

Analyst Ratings

This is a summary of recent ratings for LogicBio Therapeutics and Rubius Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
LogicBio Therapeutics00303.00
Rubius Therapeutics03202.40

LogicBio Therapeutics currently has a consensus target price of $18.50, indicating a potential upside of 135.97%. Rubius Therapeutics has a consensus target price of $13.25, indicating a potential upside of 27.40%. Given LogicBio Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe LogicBio Therapeutics is more favorable than Rubius Therapeutics.

Earnings & Valuation

This table compares LogicBio Therapeutics and Rubius Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LogicBio TherapeuticsN/AN/A$-40,130,000.00($1.78)-4.40
Rubius TherapeuticsN/AN/A$-163,460,000.00($2.08)-5.00

Rubius Therapeutics is trading at a lower price-to-earnings ratio than LogicBio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

33.8% of LogicBio Therapeutics shares are owned by institutional investors. Comparatively, 93.7% of Rubius Therapeutics shares are owned by institutional investors. 23.4% of LogicBio Therapeutics shares are owned by company insiders. Comparatively, 58.4% of Rubius Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

LogicBio Therapeutics has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500. Comparatively, Rubius Therapeutics has a beta of 2.37, indicating that its stock price is 137% more volatile than the S&P 500.

Summary

Rubius Therapeutics beats LogicBio Therapeutics on 6 of the 11 factors compared between the two stocks.

Aligos Therapeutics (NASDAQ:ALGS) and LogicBio Therapeutics (NASDAQ:LOGC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings and analyst recommendations.

Insider and Institutional Ownership

33.8% of LogicBio Therapeutics shares are held by institutional investors. 23.4% of LogicBio Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Aligos Therapeutics and LogicBio Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aligos TherapeuticsN/AN/AN/A
LogicBio TherapeuticsN/A-117.64%-76.85%

Analyst Recommendations

This is a breakdown of recent ratings for Aligos Therapeutics and LogicBio Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aligos Therapeutics00403.00
LogicBio Therapeutics00303.00

Aligos Therapeutics currently has a consensus target price of $30.50, indicating a potential upside of 41.60%. LogicBio Therapeutics has a consensus target price of $18.50, indicating a potential upside of 135.97%. Given LogicBio Therapeutics' higher probable upside, analysts plainly believe LogicBio Therapeutics is more favorable than Aligos Therapeutics.

Earnings and Valuation

This table compares Aligos Therapeutics and LogicBio Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aligos TherapeuticsN/AN/AN/AN/AN/A
LogicBio TherapeuticsN/AN/A$-40,130,000.00($1.78)-4.40


LogicBio Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$19.25-1.6%$903.15 million$69.89 million-4.59
Passage Bio logo
PASG
Passage Bio
1.9$19.43-2.7%$892.17 millionN/A0.00Earnings Announcement
Analyst Upgrade
News Coverage
Gap Down
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$23.40-7.7%$883.61 millionN/A0.00Earnings Announcement
Analyst Report
News Coverage
Gap Down
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$23.73-8.0%$857.03 millionN/A-3.92News Coverage
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.7$10.40-10.4%$844.29 millionN/A-4.86
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.54-12.1%$821.06 millionN/A0.00
Cellectis logo
CLLS
Cellectis
1.2$19.31-4.3%$820.41 million$22.99 million-10.27
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.5$24.06-6.9%$804.13 millionN/A-9.94
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.29-4.7%$783.28 million$42.74 million-225.44
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.6$5.01-4.8%$775.44 million$1.12 million-5.06Analyst Upgrade
Vaxart logo
VXRT
Vaxart
1.3$5.92-7.4%$697.18 million$9.86 million-10.03Analyst Report
Gap Up
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.86-7.3%$667.23 million$2.51 million-4.16Earnings Announcement
Analyst Report
Increase in Short Interest
Athira Pharma logo
ATHA
Athira Pharma
2.2$19.29-6.8%$626.64 millionN/A0.00Decrease in Short Interest
News Coverage
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.4$30.61-8.2%$622.00 millionN/A0.00Increase in Short Interest
Gap Down
Agenus logo
AGEN
Agenus
1.6$3.16-7.3%$600.87 million$150.05 million-2.90
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$11.02-3.1%$578.33 million$22.24 million-5.48Upcoming Earnings
Analyst Report
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.9$9.28-17.0%$573.69 millionN/A-1.35
Compugen logo
CGEN
Compugen
1.4$8.16-9.2%$558.31 million$17.80 million-22.05Analyst Downgrade
DBV Technologies logo
DBVT
DBV Technologies
1.2$5.02-7.6%$551.49 million$14.75 million-2.15Gap Up
Curis logo
CRIS
Curis
1.3$9.13-6.4%$537.00 million$10 million-11.13Increase in Short Interest
MeiraGTx logo
MGTX
MeiraGTx
1.4$13.90-2.5%$533.93 million$13.29 million-9.86Upcoming Earnings
News Coverage
Solid Biosciences logo
SLDB
Solid Biosciences
1.1$8.83-12.0%$533.77 millionN/A-4.29Upcoming Earnings
Oyster Point Pharma logo
OYST
Oyster Point Pharma
1.7$20.44-2.7%$529.60 millionN/A-5.89
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.4$11.45-6.7%$519.76 million$147.87 million-3.80Analyst Upgrade
Gap Up
Gritstone Oncology logo
GRTS
Gritstone Oncology
1.6$13.59-1.8%$513.21 million$4.36 million-4.75Upcoming Earnings
Increase in Short Interest
HARP
Harpoon Therapeutics
1.5$19.14-4.3%$485.77 million$5.78 million-8.99Upcoming Earnings
News Coverage
Gap Up
Fusion Pharmaceuticals logo
FUSN
Fusion Pharmaceuticals
1.5$11.43-2.8%$476.93 millionN/A0.00Upcoming Earnings
Opthea logo
OPT
Opthea
1.5$9.35-7.0%$394.65 millionN/A0.00Decrease in Short Interest
Cellular Biomedicine Group logo
CBMG
Cellular Biomedicine Group
0.6$19.75-0.0%$384.69 million$340,000.00-6.98
AVROBIO logo
AVRO
AVROBIO
1.7$10.54-4.6%$384.19 millionN/A-3.19
Freeline Therapeutics logo
FRLN
Freeline Therapeutics
1.5$13.50-7.9%$349.93 millionN/A0.00High Trading Volume
Gap Down
Codiak BioSciences logo
CDAK
Codiak BioSciences
1.9$15.82-2.5%$347.25 millionN/A0.00Analyst Upgrade
Cardiff Oncology logo
CRDF
Cardiff Oncology
2.0$9.18-10.1%$340.14 million$250,000.00-3.28Analyst Revision
Innate Pharma logo
IPHA
Innate Pharma
1.1$4.30-2.1%$339.62 million$96.12 million-12.65Upcoming Earnings
Aptose Biosciences logo
APTO
Aptose Biosciences
1.4$3.71-6.2%$329.60 millionN/A-5.80High Trading Volume
Decrease in Short Interest
News Coverage
SQZ Biotechnologies logo
SQZ
SQZ Biotechnologies
1.7$13.25-7.4%$329.00 millionN/A0.00Upcoming Earnings
Increase in Short Interest
Autolus Therapeutics logo
AUTL
Autolus Therapeutics
1.2$6.20-3.4%$323.95 million$2.91 million-2.16Increase in Short Interest
News Coverage
Outlook Therapeutics logo
OTLK
Outlook Therapeutics
1.6$1.81-11.0%$313.91 million$8.15 million-1.45Decrease in Short Interest
Surface Oncology logo
SURF
Surface Oncology
1.3$7.53-12.5%$306.30 million$15.36 million-11.41Upcoming Earnings
Eiger BioPharmaceuticals logo
EIGR
Eiger BioPharmaceuticals
1.6$9.24-8.3%$300.60 millionN/A-3.80Upcoming Earnings
Checkmate Pharmaceuticals logo
CMPI
Checkmate Pharmaceuticals
1.3$13.50-7.9%$290.94 millionN/A0.00
PDL BioPharma logo
PDLI
PDL BioPharma
1.1$2.47-0.0%$282.14 million$54.76 million-2.19Upcoming Earnings
CASI Pharmaceuticals logo
CASI
CASI Pharmaceuticals
1.5$2.18-9.6%$270.20 million$4.13 million-4.84News Coverage
Cabaletta Bio logo
CABA
Cabaletta Bio
1.5$10.39-11.3%$249.93 millionN/A-7.58
Applied Genetic Technologies logo
AGTC
Applied Genetic Technologies
1.5$5.06-7.1%$215.85 million$2.45 million-2.38Gap Up
ADMA Biologics logo
ADMA
ADMA Biologics
1.6$2.23-5.4%$210.84 million$29.35 million-2.59Upcoming Earnings
News Coverage
Voyager Therapeutics logo
VYGR
Voyager Therapeutics
1.7$5.58-0.7%$210.11 million$104.39 million-3.40
Axcella Health logo
AXLA
Axcella Health
1.6$5.51-3.1%$206.85 millionN/A-2.56
INmune Bio logo
INMB
INmune Bio
1.5$15.37-22.5%$206.70 millionN/A-15.85Earnings Announcement
News Coverage
Gamida Cell logo
GMDA
Gamida Cell
1.4$8.43-6.3%$204.18 millionN/A-5.90Upcoming Earnings
Increase in Short Interest
Gap Up
This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.